Bolt Biotherapeutics (BOLT) Total Current Liabilities (2020 - 2026)

Bolt Biotherapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $7.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 45.86% year-over-year to $7.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.3 million (down 45.86% YoY) and the FY2025 annual result came in at $8.4 million, down 46.8% from the prior year.
• Total Current Liabilities slipped to $7.3 million in Q1 2026 per BOLT's latest filing, from $8.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $24.2 million in Q3 2022 and troughed at $7.3 million in Q1 2026.
• A 5-year average of $16.4 million and a median of $17.6 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 60.72% in 2022, then plunged 46.8% in 2025.
• Over 5 years, Total Current Liabilities stood at $23.1 million in 2022, then fell by 11.51% to $20.5 million in 2023, then decreased by 22.49% to $15.9 million in 2024, then slumped by 46.8% to $8.4 million in 2025, then declined by 12.95% to $7.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $7.3 million, $8.4 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.